المؤلفون: Akihiro Tamori, Atsushi Hagihara, Hideki Fujii, Hiroji Shinkawa, Hiroyuki Motoyama, Kanako Yoshida, Kohei Kotani, Koji Rinka, Masaru Enomoto, Naoshi Odagiri, Norifumi Kawada, Sawako Uchida-Kobayashi, Shogo Tanaka, Shoji Kubo, Takayoshi Nishioka, Tooru Miyazaki, 久保 正二, 元山 宏行, 吉田 香奈子, 宮崎 徹, 小田桐 直志, 小谷 晃平, 打田（小林） 佐和子, 新川 寛二, 林下 晃士, 榎本 大, 河田 則文, 田中 肖吾, 田守 昭博, 萩原 淳司, 藤井 英樹, 西岡 孝芳

المصدر: 肝臓 / Kanzo. 2020, 61(11):597

المؤلفون: Riviere, M.-K., Yuan, Y., Dubois, F., Zohar, Sarah

المساهمون: Université Paris Descartes - Paris 5 (UPD5), Université Pierre et Marie Curie - Paris 6 (UPMC), Institut de Recherches Internationales Servier (IRIS-Servier), Centre National de la Recherche Scientifique (CNRS), Centre Médical MD Anderson, The University of Texas Health Science Center at Houston (UTHealth)

المصدر: ISSN: 0959-5341 ; Journal of the Statistical Society of London ; https://hal.sorbonne-universite.fr/hal-01298649Test ; Journal of the Statistical Society of London, 2015, 64 (1), pp.215-229. ⟨10.1111/rssc.12072⟩.

مصطلحات موضوعية: Combination, Cytotoxicity, Dose finding, Molecularly targeted agent, Phase I–II, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology

العلاقة: hal-01298649; https://hal.sorbonne-universite.fr/hal-01298649Test; https://hal.sorbonne-universite.fr/hal-01298649/documentTest; https://hal.sorbonne-universite.fr/hal-01298649/file/Riviere_2015_A_Bayesian_dose.pdfTest

الإتاحة: https://doi.org/10.1111/rssc.12072Test
https://hal.sorbonne-universite.fr/hal-01298649Test
https://hal.sorbonne-universite.fr/hal-01298649/documentTest
https://hal.sorbonne-universite.fr/hal-01298649/file/Riviere_2015_A_Bayesian_dose.pdfTest

المؤلفون: Biard, Lucie, Cheng, Bin, Manji, Gulam A, Lee, Shing M

المصدر: J Biopharm Stat ; ISSN:1520-5711 ; Volume:31 ; Issue:2

مصطلحات موضوعية: Dose-finding, disease progression, immunotherapy, late-onset toxicity, molecularly-targeted agent

العلاقة: https://doi.org/10.1080/10543406.2020.1814796Test; https://pubmed.ncbi.nlm.nih.gov/32931360Test

الإتاحة: https://doi.org/10.1080/10543406.2020.1814796Test
https://pubmed.ncbi.nlm.nih.gov/32931360Test

المؤلفون: Gadducci A., Cosio S.

المساهمون: Gadducci, A., Cosio, S.

مصطلحات موضوعية: Chemotherapy, Endocrine therapy, Low grade ovarian serous carcinoma, Mitogen activated protein kinase (MAPK), Molecularly-targeted agent, Surgery

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32456205; volume:12; issue:5; firstpage:1336; journal:CANCERS; http://hdl.handle.net/11568/1070217Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85085524339

الإتاحة: https://doi.org/10.3390/cancers12051336Test
http://hdl.handle.net/11568/1070217Test

المؤلفون: Kenji Tamura, Akihiro Hirakawa, Yasuhiro Fujiwara, Yumiko Kobayashi, Fumie Kinoshita, Kan Yonemori, Asuka Kawachi, Pamela Jo Harris, Hitomi Sumiyoshi Okuma, Larry Rubinstein, Naoko Takebe

المصدر: Cancer Science

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, relative dose intensity, Antineoplastic Agents, recommended phase 2 dose, 03 medical and health sciences, Dose finding, Young Adult, 0302 clinical medicine, phase 1 trial, Clinical Research, Internal medicine, Neoplasms, medicine, Humans, Longitudinal Studies, Molecular Targeted Therapy, Aged, Response rate (survey), Aged, 80 and over, Lower grade, Toxicity data, maximum tolerated dose, Clinical Trials, Phase I as Topic, business.industry, Disease progression, Phase 1 trials, General Medicine, Original Articles, Middle Aged, Dose intensity, Surgery, 030104 developmental biology, molecularly targeted agent, Treatment Outcome, 030220 oncology & carcinogenesis, Toxicity, Disease Progression, Original Article, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b842b36a941406871539f21538246817Test
http://europepmc.org/articles/PMC5765308Test

المساهمون: Kim, Nam Kyu, Hur, Hyuk, Kim, Jin Soo, Roh, Jae Kyung, Min, Byung Soh, Sohn, Seung Kook, Ahn, Joong Bae, Cho, Chang Hwan, Choi, Jin Sub

المصدر: T200800524.pdf

مصطلحات موضوعية: Colorectal cancer, Liver metastasis, Molecularly targeted agent, Curative resection

وصف الملف: 184~191

العلاقة: Journal of the Korean Society of Coloproctology; J01864; OAK-2008-00594; https://ir.ymlib.yonsei.ac.kr/handle/22282913/106714Test; Colorectal cancer; Liver metastasis; Molecularly targeted agent; Curative resection; T200800524; Journal of the Korean Society of Coloproctology, Vol.24(3) : 184-191, 2008; 49320

الإتاحة: https://doi.org/10.3393/jksc.2008.24.3.184Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/106714Test

المؤلفون: Muenz, Daniel G., Taylor, Jeremy M. G., Braun, Thomas M.

مصطلحات موضوعية: Immunotherapy, Molecularly targeted agent, Randomization, Dose finding, Clinical trial, Biologically optimal dose, Statistics and Numeric Data, Science

وصف الملف: application/pdf

العلاقة: Muenz, Daniel G.; Taylor, Jeremy M. G.; Braun, Thomas M. (2019). "Phase I–II trial design for biologic agents using conditional auto‐regressive models for toxicity and efficacy." Journal of the Royal Statistical Society: Series C (Applied Statistics) 68(2): 331-345.; https://hdl.handle.net/2027.42/147824Test; Journal of the Royal Statistical Society: Series C (Applied Statistics); Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Souquet, P. J., Baldini, E., Cappuzzo, F., Chouaid, C., Dowlati, A., Sanborn, R., Lopez‐Chavez, A., Grohe, C., Huber, R. M., Harbison, C. T., Baudert, C., Lestini, B. J. and Ramalingam, S. S. ( 2015 ) Activity and safety of nivolumab, an anti‐PD‐1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non‐small‐cell lung cancer (CheckMate 063): a Phase 2, single‐arm trial. Lancet Oncol., 16, 257 – 265.; Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., Dronca, R., Gangadhar, T. C., Patnaik, A., Zarour, H., Joshua, A. M., Gergich, K., Elassaiss‐Schaap, J., Algazi, A., Mateus, C., Boasberg, P., Tumeh, P. C., Chmielowski, B., Ebbinghaus, S. W., Li, X. N., Kang, S. P. and Ribas, A. ( 2013 ) Safety and tumor responses with lambrolizumab (anti‐PD‐1) in melanoma. New Engl. J. Med., 369, 134 – 144.; Jain, R. K., Lee, J. J., Hong, D., Markman, M., Gong, J., Naing, A., Wheler, J. and Kurzrock, R. ( 2010 ) Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin. Cancer Res., 16, 1289 – 1297.; Jin, I., Liu, S., Thall, P. and Yuan, Y. ( 2014 ) Using data augmentation to facilitate conduct of Phase I/II clinical trials with delayed outcomes. J. Am. Statist. Ass., 109, 525 – 536.; Lipson, E. J. and Drake, C. G. ( 2011 ) Ipilimumab: an anti‐ctla‐4 antibody for metastatic melanoma. Clin. Cancer Res., 17, 6958 – 6962.; Liu, S. and Johnson, V. E. ( 2016 ) A robust Bayesian dose‐finding design for phase I/II clinical trials. Biostatistics, 17, 249 – 263.; Luce, D. ( 1959 ) Individual Choice Behavior. New York: Wiley.; Minh, D. D. L. and Minh, D. L. P. ( 2015 ) Understanding the Hastings algorithm. Communs Statist. Simuln Computn, 44, 332 – 349.; O’Quigley, J., Pepe, M. and Fisher, L. ( 1990 ) Continual reassessment method: a practical design for Phase 1 clinical trials in cancer. Biometrics, 46, 33 – 48.; Plummer, M. ( 2003 ) JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. In Proc. 3rd Int. Wrkshp Distributed Statistical Computing (eds K. Hornik, F. Leisch and A. Zeileis).; Postel‐Vinay, S., Arkenau, H.‐T., Olmos, D., Ang, J., Barriuso, J., Ashley, S., Banerji, U., De‐Bono, J., Judson, I. and Kaye, S. ( 2009 ) Clinical benefit in Phase‐I trials of novel molecularly targeted agents: does dose matter? Br. J. Cancer, 100, 1373 – 1378.; Riviere, M.‐K., Yuan, Y., Dubois, F. and Zohar, S. ( 2015 ) A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent. Appl. Statist., 64, 215 – 229.; Riviere, M.‐K., Yuan, Y., Jourdan, J.‐H., Dubois, F. and Zohar, S. ( 2016 ) Phase I/II dose‐finding design for molecularly targeted agent: plateau determination using adaptive randomization. Statist. Meth. Med. Res., 27, 466 – 479.; Storer, B. E. ( 1989 ) Design and analysis of Phase I clinical trials. Biometrics, 45, 925 – 937.; Thall, P. F. and Cook, J. D. ( 2004 ) Dose‐finding based on efficacy‐toxicity trade‐offs. Biometrics, 60, 684 – 693.; Thall, P. F. and Nguyen, H. Q. ( 2012 ) Adaptive randomization to improve utility‐based dose‐finding with bivariate ordinal outcomes. J. Biopharm. Statist., 22, 785 – 801.; Thall, P. F. and Russell, K. E. ( 1998 ) A strategy for dose‐finding and safety monitoring based on efficacy and adverse outcomes in Phase I/II clinical trials. Biometrics, 54, 251 – 264.; Wages, N. A. and Tait, C. ( 2015 ) Seamless Phase I/II adaptive design for oncology trials of molecularly targeted agents. J. Biopharm. Statist., 25, 903 – 920.; Wall, M. M. ( 2004 ) A close look at the spatial structure implied by the CAR and SAR models. J. Statist. Planng Inf., 121, 311 – 324.; Yuan, Y., Nguyen, H. Q. and Thall, P. F. ( 2016 ) Bayesian Designs for Phase I‐II Clinical Trials. Boca Raton: Chapman and Hall–CRC.; Zang, Y., Lee, J. J. and Yuan, Y. ( 2014 ) Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clin. Trials, 11, 319 – 327.; Besag, J. ( 1974 ) Spatial interaction and the statistical analysis of lattice systems (with discussion). J. R. Statist. Soc. B, 36, 192 – 236.; Braun, T. M. ( 2002 ) The bivariate continual reassessment method: extending the CRM to Phase I trials of two competing outcomes. Contr. Clin. Trials, 23, 240 – 256.; Cai, C., Yuan, Y. and Ji, Y. ( 2014 ) A Bayesian dose finding design for oncology clinical trials of combinational biological agents. Appl. Statist., 63, 159 – 173.; Cheung, Y. K. and Chappell, R. ( 2000 ) Sequential designs for Phase I clinical trials with late‐onset toxicities. Biometrics, 56, 1177 – 1182.; Cressie, N. A. C. ( 2015 ) Statistics for Spatial Data, vol. II, Lattice Data, ch. 6. Hoboken: Wiley.; Cunanan, K. and Koopmeiners, J. S. ( 2014 ) Evaluating the performance of copula models in Phase I‐II clinical trials under model misspecification. BMC Med. Res. Methodol., 14, no. 51, 1 – 11.; Faries, D. ( 1994 ) Practical modifications of the continual reassessment method for Phase I cancer clinical trials. J. Biopharm. Statist., 4, 147 – 164.; Goodman, S. N., Zahurak, M. L. and Piantadosi, S. ( 1995 ) Some practical improvements in the continual reassessment method for Phase I studies. Statist. Med., 14, 1149 – 1161.; Gooley, T. A., Martin, P. J., Fisher, L. D. and Pettinger, M. ( 1994 ) Simulation as a design tool for Phase I/II clinical trials: an example from bone marrow transplantation. Contr. Clin. Trials, 15, 450 – 462.; Guo, B. and Li, Y. ( 2015 ) Bayesian dose‐finding designs for combination of molecularly targeted agents assuming partial stochastic ordering. Statist. Med., 34, 859 – 875.

الإتاحة: https://doi.org/10.1111/rssc.12314Test
https://hdl.handle.net/2027.42/147824Test

المؤلفون: Akiko Kuwahara, Hideaki Takahashi, Hiroyuki Okuyama, Izumi Ohno, Masafumi Ikeda, Satoshi Shimizu, Shuichi Mitsunaga, Takuji Okusaka, 光永 修一, 大野 泉, 奥坂 拓志, 奥山 浩之, 桑原 明子, 池田 公史, 清水 怜, 高橋 秀明

المصدر: 日本インターベンショナルラジオロジー学会雑誌 / The Official Journal of the Japanese Society of Interventional Radiology. 2013, 28(4):403

المؤلفون: Porta C., Toscani I., Czarnecka A. M., Szczylik C. A.

المساهمون: Porta, C., Toscani, I., Czarnecka, A. M., Szczylik, C. A.

مصطلحات موضوعية: Checkpoint inhibitor, combination, cytokine, immunotherapy, molecularly targeted agent, vaccine, Angiogenesis Inhibitor, Animal, Antineoplastic Agent, Antineoplastic Combined Chemotherapy Protocol, Carcinoma, Renal Cell, Drug Delivery System, Forecasting, Human, Kidney Neoplasm, Treatment Outcome

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27960591; info:eu-repo/semantics/altIdentifier/wos/WOS:000394439900002; volume:17; issue:2; firstpage:151; lastpage:162; numberofpages:12; journal:EXPERT OPINION ON BIOLOGICAL THERAPY; http://hdl.handle.net/11571/1301866Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85009990529

الإتاحة: https://doi.org/10.1080/14712598.2017.1271869Test
http://hdl.handle.net/11571/1301866Test

المؤلفون: Shihao Shen, Jun Yin

المصدر: Journal of biometrics & biostatistics

مصطلحات موضوعية: Oncology, medicine.medical_specialty, medicine.medical_treatment, Cancer immunotherapy, Bioinformatics, Phase (combat), Article, Dose finding, Phase I, Internal medicine, medicine, Toxicity score, Cumulative toxicity, Severe toxicity, Toxicity profile, business.industry, Dose-finding, Molecularly targeted agent, Cancer, medicine.disease, Clinical trial, Late toxicity, business, Prolonged treatment

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::313908a50c529a142e9846a1476f4d67Test
https://doi.org/10.4172/2155-6180.1000324Test